



Impact of Changes in Clinical Microbiology Laboratory Location and Ownership on the Practice of Infectious Diseases

Michael Pentella,^a Melvin P. Weinstein,^b  Susan E. Beekmann,^c Philip M. Polgreen,^c Richard T. Ellison III^d

^aCollege of Public Health, University of Iowa, Iowa City, Iowa, USA

^bDepartments of Medicine and Pathology & Laboratory Medicine, Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA

^cDivision of Infectious Diseases, University of Iowa Carver College of Medicine, Iowa City, Iowa, USA

^dDivision of Infectious Diseases and Immunology, University of Massachusetts Medical School, Worcester, Massachusetts, USA

ABSTRACT The number of onsite clinical microbiology laboratories in hospitals is decreasing, likely related to the business model for laboratory consolidation and labor shortages, and this impacts a variety of clinical practices, including that of banking isolates for clinical or epidemiologic purposes. To determine the impact of these trends, infectious disease (ID) physicians were surveyed regarding their perceptions of offsite services. Clinical microbiology practices for retention of clinical isolates for future use were also determined. Surveys were sent to members of the Infectious Diseases Society of America's (IDSA) Emerging Infections Network (EIN). The EIN is a sentinel network of ID physicians who care for adult and/or pediatric patients in North America and who are members of IDSA. The response rate was 763 (45%) of 1,680 potential respondents. Five hundred forty (81%) respondents reported interacting with the clinical microbiology laboratory. Eighty-six percent of respondents thought an onsite laboratory very important for timely diagnostic reporting and ongoing communication with the clinical microbiologist. Thirty-five percent practiced in institutions where the core microbiology laboratory has been moved offsite, and an additional 7% ($n = 38$) reported that movement of core laboratory functions offsite was being considered. The respondents reported that only 24% of laboratories banked all isolates, with the majority saving isolates for less than 30 days. Based on these results, the trend toward centralized core laboratories negatively impacts the practice of ID physicians, potentially delays effective implementation of prompt and targeted care for patients with serious infections, and similarly adversely impacts infection control epidemiologic investigations.

KEYWORDS clinical microbiology laboratory, remote laboratory, laboratory storage, isolate retention

During the past 3 decades, clinical laboratories have faced a new business model driven by a reimbursement system that encourages economies of scale and large-volume testing (1, 2). At the same time, there have been the additional issues of increasing shortages of experienced microbiologists in the labor force and the emergence of new complex and costly diagnostic technologies (2). In response to these economic realities, a number of clinical microbiology laboratories have moved to locations remote from the main hospital facility in order to expand laboratory capacity, whereas others have consolidated laboratory facilities in multihospital systems (3–6). While these consolidations can offer economies of scale and the more ready introduction of sophisticated expensive technologies, these remote-site laboratories present challenges for both quality of services and communication (6, 7). The partnership of the clinical microbiologist and the infectious disease physician can result in better use of laboratory services and improvement in patient care; distance can strain, if not com-

Citation Pentella M, Weinstein MP, Beekmann SE, Polgreen PM, Ellison RT, III. 2020. Impact of changes in clinical microbiology laboratory location and ownership on the practice of infectious diseases. *J Clin Microbiol* 58:e01508-19. <https://doi.org/10.1128/JCM.01508-19>.

Editor Karen C. Carroll, Johns Hopkins University School of Medicine

Copyright © 2020 American Society for Microbiology. All Rights Reserved.

Address correspondence to Michael Pentella, michael-pentella@uiowa.edu.

Received 10 September 2019

Returned for modification 2 October 2019

Accepted 7 February 2020

Accepted manuscript posted online 19 February 2020

Published 23 April 2020

pletely eliminate, these benefits (8, 9). Beyond this, as off-site laboratories lose a primary relationship with a given institution and may in fact become separate for-profit entities, the costs associated with retaining clinical isolates for future epidemiologic may now require formal budgetary justification (9).

To determine the impact of these trends, infectious disease physicians were surveyed regarding their experiences with offsite services. This survey was not designed to determine the impact of offsite laboratory services on the quality of patient care, but rather to describe the impact on infectious diseases physicians. The move away from hospital-based laboratories also may have decreased the number of institutions which save isolates; saving isolates allows repeat or additional testing for a variety of needs, including investigations for infection control, for public health purposes, and for quality control purposes. We also were interested in whether clinical isolates were retained for future use and in policies regarding this practice.

MATERIALS AND METHODS

We sent a twelve-question primary survey and a five-question subsurvey on isolate retention to physician members of the Infectious Diseases Society of America's (IDSA) Emerging Infections Network (EIN). The EIN is a sentinel network of infectious disease (ID) physicians who care for adult and/or pediatric patients in North America and who are members of IDSA (10). The survey was collaboratively developed by us and reviewed by ID physicians currently in clinical practice for content validity and pilot testing. On 22 May 2018, all 1,830 members of the EIN received the confidential survey by e-mail link or by facsimile. Nonresponders received two reminders, and physicians who had joined the EIN but had not yet responded to any surveys were excluded ($n = 150$), resulting in a denominator of 1,680 physician members. An opt-out option was provided for physicians who did not interact with the clinical microbiology laboratory in their primary institutions. The survey remained open until 14 June 2018.

The physicians were asked to indicate whether any of a given list of clinical microbiology laboratory services were performed onsite in their primary institutions, as well as their satisfaction with this laboratory's services; they were also asked whether any core microbiology functions had been moved offsite and, if so, a series of questions about the offsite location. Also, physicians were queried as to whether the microbiology laboratory banked any isolates and, if so, were asked to open a second link to respond to a brief subsurvey on isolate retention. This subsurvey asked which isolates were saved and for how long, whether these saved isolates had been used, and whether there was any impact on clinical practice. Practice information for each respondent, including employment, geographic location, and years of practice, was imported from an EIN database. Not all respondents answered all questions, so totals for individual questions vary. Chi-square and Fisher's exact tests were used for univariate analyses. Data were analyzed using SAS software version 9.4 (SAS Institute, Cary, NC).

RESULTS

The overall rate of response to the survey was 763 (45%) of 1,680 potential respondents, with 441 of the 1,680 (26%) answering only the clinical microbiology laboratory services survey, 95 (6%) respondents answering only the isolate retention (banking) subsurvey, and 227 (13.5%) responding to both. All regions of the United States were well represented (Table 1). The years of experience since infectious disease fellowship ranged from less than 5 years to more than 25 years, with the largest number of respondents (29%) having from 5 to 14 years of experience. A university or medical school work setting accounted for 40% of respondents, and 48% (364/763) were associated with community and nonuniversity teaching hospitals. A sizable number of respondents ($n = 190$) practiced in institutions where the core microbiology laboratory had been moved off site, and an additional 38 reported that movement of core laboratory functions offsite was being considered.

Eighty-six percent of respondents thought an onsite laboratory to be very important for timely diagnostic reporting and ongoing communication with the clinical microbiologist. Slightly fewer felt that onsite laboratories were important for education/teaching (75%, very important; 20%, slightly or moderately important). Respondents most often reported that their primary microbiology laboratories always met their expectations with regard to communication with laboratory management or the laboratory director (64%) and with microbiology laboratory bench personnel (59%). The overall quality and accuracy of microbiology laboratory results always met expectations for 50% of respondents, followed by electronic reporting of microresults (48%) and handling of mycobacteriology specimens and issues (46%). Turnaround time for microbiology laboratory results met respondents' expectations least often, with 35%

TABLE 1 Practice characteristics of 763 respondents^a

Category	Characteristic	No. (%) of respondents
Infectious diseases practice	Adult	572 (75)
	Pediatric	191 (25)
U.S. Census Bureau division	New England	52 (7)
	Mid Atlantic	114 (15)
	East North Central	106 (14)
	West North Central	79 (10)
	South Atlantic	134 (18)
	East South Central	37 (5)
	West South Central	52 (7)
	Mountain	40 (5)
	Pacific	141 (18)
	Puerto Rico	1 (0.1)
No. of years' experience since ID fellowship	Canada	7 (1)
	<5	173 (23)
	5–14	225 (29)
	15–24	145 (19)
	≥25 years	220 (29)
Employment	Hospital/clinic	224 (32)
	Private/group practice	167 (22)
	University/medical school	305 (40)
	VA and military	43 (6)
	State government	4 (0.5)
Primary hospital type	Community	163 (22)
	Nonuniversity teaching	201 (26)
	University	323 (42)
	VA hospital or DOD	48 (6)
	City/country	28 (4)

^aDOD, U.S. Department of Defense; VA, Veterans Administration.

saying their expectations were always met and 63% indicating that their expectations were either mostly or sometimes met.

In the area of posttesting physician needs, the respondents reported that only 24% of laboratories banked all isolates, with the majority saving isolates for less than 30 days. However, 72% of the laboratories would save isolates on request. Of the respondents, over 50% had made use of banked isolates in the last year, with 160 (51%) of 321 doing so for direct clinical care and 168 (54%) for epidemiological investigations. Additionally, 166 (52%) respondents indicated that there had been a time in the past year when an isolate was needed but was not available because of the laboratory's retention policy.

Five hundred forty (81%) respondents reported interacting with the clinical microbiology laboratory, and the laboratory services available onsite at their institutions are summarized in Table 2. Those services include the following: 74% have after-hours Gram stain interpretation; 88% have on-site blood cultures, but only 61% have blood culture rapid identification methods; 78% have respiratory virus panel testing, but only 61% have *Legionella* urinary antigen testing; 84% have onsite *Clostridioides difficile* testing; 50% have adopted matrix-assisted laser desorption ionization-time of flight (MALDI-TOF) technology for bacterial identification.

Two hundred nine respondents (all of those whose institutions had moved functions offsite plus 19 of those whose institutions were considering such a move) then answered six questions about their offsite microbiology laboratory. Of the respondents who had experience with an offsite laboratory, 74% perceived that the offsite laboratory has a negative impact on overall infectious disease patient care and outcomes (either major or minor), with the primary negative effects relating to turnaround time and communication with the laboratory. Of the respondents who had experience with an offsite laboratory, 57% said that the transport time to the offsite location was greater than 30 min. Ten percent of these respondents reported a positive impact (either minor or major) most often related to overall availability of lab services and technologies. In

TABLE 2 Lab services performed on site in respondents' primary institution^a

Procedure	No. (%) with response		
	Available onsite	Offsite only	Not sure/ not answered
Gram stain interpretation, Monday through Friday, 8 a.m.–3 p.m.	491 (91)	25 (5)	24 (4)
Blood culture bottle processing	476 (88)	44 (8)	20 (4)
<i>C. difficile</i> testing (e.g., GDH, NAAT)	453 (84)	50 (9)	37 (7)
Identification and susceptibility testing of sterile-site isolates	429 (80)	60 (11)	51 (9)
Respiratory virus panel testing (e.g., RSV, influenza)	421 (78)	63 (12)	56 (10)
Blood smears for infection (e.g., malaria, <i>Anaplasma</i> , <i>Ehrlichia</i>)	403 (75)	64 (12)	73 (13)
Gram stain interpretation, Monday through Friday, 11 p.m.–6 a.m.	399 (74)	37 (7)	104 (19)
AFB stains and culture	338 (63)	105 (19)	97 (18)
GI pathogen panel (e.g., <i>Salmonella</i> , norovirus)	335 (62)	94 (17)	111 (21)
Blood culture rapid ID (e.g., BioFire, Verigene)	331 (61)	90 (17)	119 (22)
<i>Legionella</i> urinary antigen	327 (61)	97 (18)	116 (21)
MALDI-TOF identification system for bacteriology	270 (50)	121 (22)	149 (28)
NAAT for <i>Mycobacterium tuberculosis</i>	231 (43)	158 (29)	151 (28)

^an = 540. GDH, glutamate dehydrogenase; NAAT, nucleic acid amplification testing; RSV, respiratory syncytial virus; AFB, acid-fast bacillus; GI, gastrointestinal.

addition, 47% felt that an offsite laboratory adversely impacted infectious disease medical education. Only 65% felt that infectious disease physicians have any input into microbiology laboratory policies that affect their practice.

DISCUSSION

While the model of test delivery is changing, the science of clinical microbiology is becoming more complex. The need for a strong partnership between the infectious disease physician and the clinical microbiology laboratory has always been important, but it has become even greater in recent years given the development of new methods, instruments, automation, and the desire for shorter turnaround times (8). Moreover, optimal utilization of newer technologies, such as MALDI-TOF, multiplex PCR systems, next-generation sequencing, and rapid antimicrobial resistance determination, will be dependent on consultation between the infectious disease physician and the laboratory director.

Based on the results of this survey, the trend toward centralized core laboratories has impacted the practice of infectious disease physicians and, in their perception, not in a positive way. A marked majority of the survey respondents indicated that they felt that onsite testing is important for timely diagnostic reporting and ongoing communication with clinical microbiology. However, 35% of the respondents reported that their clinical microbiology laboratory is now located offsite, with more than half of these laboratories being more than 30 min from their institution, which would impede any possibility of a brief in-person meeting or the possibility of the infectious disease physician quickly visiting the laboratory. This points to the need for laboratory directors to consider alternate means to connect with the infectious disease physician community to build the necessary communication channels.

Importantly, many respondents to this survey are not satisfied with the services provided by their clinical microbiology laboratory, given that the laboratories were always meeting their expectations with regard to only 35% to 64% of six measures. This lack of satisfaction is supported by the reported limitations in clinical microbiology services at the respondents' hospitals, as only 74% had known on-site Gram stain interpretation after hours, and many clinical microbiology laboratories are not keeping up with new technology, with only 61% of the facilities providing rapid blood culture identification methods and only 50% having adopted MALDI-TOF technology. As another indicator of service, infectious disease physician respondents were asked about the retention of isolates by the clinical microbiology laboratory. Seventy-two percent responded that they could have an isolate saved if they requested it, yet over 50% had a need for a retained isolate in the past year.

A significant impact of an offsite clinical microbiology was on medical education, as

noted by 47% of the respondents. However, the respondents also felt that they did not have much impact on the operations of the laboratory, and the lack of communication impedes the ability of microbiologists and clinicians to work together in optimizing the selection and utilization of the new technological advances in clinical microbiology, such as rapid blood culture identification and MALDI-TOF systems (5).

From the available data in the literature, consideration of costs (10) is a major factor in the decision to send specimens to an outside laboratory, but administrators do not quantify or know the cost of keeping patients in hospital longer or the cost of additional tests or empirical treatment until culture or other results return (11). In addition, despite the recommendations that the clinical microbiologist collaborate in antibiotic stewardship programs (10), when the laboratory is offsite, there is not sufficient opportunity for interaction between the infectious disease physician and the clinical microbiology laboratory to allow this. It is possible that the use of video conferencing and tele-microbiology may compensate for the lack of direct interactions, but such services do not appear to be routinely available at this time. Beyond all of these issues, ongoing efforts to improve the quality of patient care, decrease length of stay, and meet benchmarks such as for sepsis protocols (e.g., treating patients at the earliest possible time) are all driving the need for near-patient diagnostics, and offsite laboratories may have difficulty meeting these needs (10).

Another concern arising from the move to centralized non-institution-based laboratories is the ability of the microbiology laboratory to assist in infection control and public health activities (6, 9, 12–14) and, specifically, the finding that only a minority of laboratories are now retaining isolates. There has been increasing concern about health care-associated infections, cross transmission of multidrug-resistant organisms, and point source outbreaks within hospitals and the general community. However, the ability to determine actual cross transmission events is dependent on the ability to type or sequence pathogens, and multiple studies have shown that for epidemiologic purposes, typing needs to be performed using molecular typing methods such as pulsed-field gel electrophoresis or whole-genome sequencing (15–17). Such additional characterization can be done only if isolates potentially linked to cross transmission events or presumed outbreaks have been retained, and if measures are not in place to retain such isolates, the public health benefit of identifying and controlling outbreaks is lost. While the ability to retain isolates is independent of the location of the laboratory, retention of isolates serves as an indicator of meeting an essential need of the physician.

Our findings are subject to a number of limitations. To maximize the response rate, the survey was designed to be relatively straightforward for respondents to complete. Consequently, more detailed analyses of the use of newer technologies and the breakdown of services available on and off site were not possible. While the EIN represents about 18% of IDSA physician members and about 20% of subspecialty board-certified physicians, our members are not randomly selected. Since our members “self-select” to join the EIN, we do not make any claims that our members are representative of the broad population of infectious disease physicians. This was a descriptive survey which reflects the perceptions and opinions of the responding infectious disease physicians and should be validated with additional data about specific interactions between infectious disease physicians and laboratory personnel. Moreover, the perceptions and opinions of laboratory directors were not incorporated into the survey.

Conclusions. It has been recommended that “maintaining high-quality clinical microbiology laboratories on the site of the institution that they serve is the current best approach for managing today’s problems of emerging infectious diseases and antimicrobial agent resistance by providing good patient care outcomes that actually save money” (9). Unfortunately, the findings of this survey indicate that the shift from institution-based to core laboratory facilities is having a negative impact on infectious disease physicians and their relationship with the clinical microbiology laboratory. A

yet-unanswered question is that of the impact of this trend on the care of the patient, the cost of medical care for those with serious infections, and the public health issues of antimicrobial resistance and emerging infectious diseases. Going forward, it will be important for institutions to develop key performance indicators related to laboratory services so that the relative utility of on-site and off-site laboratories in all of these areas can be better defined.

ACKNOWLEDGMENTS

This publication was supported by a Cooperative Agreement (1 U50 CK000477) funded by the Centers for Disease Control and Prevention. We report no conflicts of interest relevant to this article.

The contents are solely the responsibility of the authors and do not necessarily represent the official views of the Centers for Disease Control and Prevention or the Department of Health and Human Services.

REFERENCES

1. Van Eldere J. 2005. Changing needs, opportunities and constraints for the 21st century microbiology laboratory. *Clin Microbiol Infect* 11:15–18. <https://doi.org/10.1111/j.1469-0691.2005.01084.x>.
2. Finch R, Hryniewicz W, Van Eldere J. 2005. Report of working group 2: healthcare needs in the organisation and management of infection. *Clin Microbiol Infect* 11(Suppl 1):41–45. <https://doi.org/10.1111/j.1469-0691.2005.01090.x>.
3. Baron EJ. 2002. Speculations on the microbiology laboratory of the future. *Clin Infect Dis* 35:S84–S87. <https://doi.org/10.1086/341926>.
4. Shah H. 2013. Consolidation of the microbiology laboratory services: a mini-review of finances and quality of care. *Lab Med* 44:86–89. <https://doi.org/10.1309/LM9FESITVA22BDOM>.
5. Sautter RL, Thomson RB, Jr. 2015. Consolidated clinical microbiology laboratories. *J Clin Microbiol* 53:1467–1472. <https://doi.org/10.1128/JCM.02569-14>.
6. Vandenberg O, Kozlakidis Z, Schrenzel J, Struelens MJ, Breuer J. 2018. Control of infectious diseases in the era of European clinical microbiology laboratory consolidation: new challenges and opportunities for the patient and for public health surveillance. *Front Med (Lausanne)* 5:15. <https://doi.org/10.3389/fmed.2018.00015>.
7. Procop GW, Microbiology Resource Committee, College of American Pathologists, Winn W. 2003. Outsourcing microbiology and offsite laboratories. Implications on patient care, cost savings, and graduate medical education. *Arch Pathol Lab Med* 127:623–624.
8. Baron EJ, Miller JM, Weinstein MP, Richter SS, Gilligan PH, Thomson RB, Jr, Bourbeau P, Carroll KC, Kehl SC, Dunne WM, Robinson-Dunn B, Schwartzman JD, Chapin KC, Snyder JW, Forbes BA, Patel R, Rosenblatt JE, Pritt BS. 2013. A guide to utilization of the microbiology laboratory for diagnosis of infectious diseases: 2013 recommendations by the Infectious Diseases Society of America (IDSA) and the American Society for Microbiology (ASM). *Clin Infect Dis* 57:e22–e121. <https://doi.org/10.1093/cid/cit278>.
9. Peterson LR, Hamilton JD, Baron EJ, Tompkins LS, Miller JM, Wilfert CM, Tenover FC, Thomson RB, Jr. 2001. Role of clinical microbiology laboratories in the management and control of infectious diseases and the delivery of health care. *Clin Infect Dis* 32:605–611. <https://doi.org/10.1086/318725>.
10. Plebani M. 2015. Clinical laboratories: production industry or medical services? *Clin Chem Lab Med* 53:995–1004. <https://doi.org/10.1515/cclm-2014-1007>.
11. Barlam TF, Cosgrove SE, Abbo LM, MacDougall C, Schuetz AN, Septimus EJ, Srinivasan A, Dellit TH, Falck-Ytter YT, Fishman NO, Hamilton CW, Jenkins TC, Lipsett PA, Malani PN, May LS, Moran GJ, Neuhauser MM, Newland JG, Ohl CA, Samore MH, Seo SK, Trivedi KK. 2016. Implementing an antibiotic stewardship program: guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America. *Clin Infect Dis* 62:e51–e77. <https://doi.org/10.1093/cid/ciw118>.
12. Pillai SK, Beekmann SE, Santibanez S, Polgreen PM. 2014. The Infectious Diseases Society of America Emerging Infections Network—bridging the gap between clinical infectious diseases and public health. *Clin Infect Dis* 58:991–996. <https://doi.org/10.1093/cid/cit932>.
13. Wilson ME, Spencer RC. 1999. Laboratory role in the management of hospital acquired infections. *J Hosp Infect* 42:1–6. <https://doi.org/10.1053/jhin.1998.0545>.
14. Simoes AS, Couto I, Toscano C, Goncalves E, Povoia P, Viveriros M, Lapao L. 2016. Prevention and control of antimicrobial resistant healthcare-associated infections: the microbiology laboratory rocks! *Front Microbiol* 7:855. <https://doi.org/10.3389/fmicb.2016.00855>.
15. Snitkin ES, Zelazny AM, Thomas PJ, Stock F, NISC Comparative Sequencing Program, Henderson DK, Palmore TN, Segre JA. 2012. Tracking a hospital outbreak of carbapenem-resistant *Klebsiella pneumoniae* with whole-genome sequencing. *Sci Transl Med* 4:148ra116. <https://doi.org/10.1126/scitranslmed.3004129>.
16. Gilchrist CA, Turner SD, Riley MF, Petri WA, Hewlett EL. 2015. Whole-genome sequencing in outbreak analysis. *Clin Microbiol Rev* 28:541–563. <https://doi.org/10.1128/CMR.00075-13>.
17. Aanensen DM, Feil EJ, Holden MT, Dordel J, Yeats CA, Fedosejev A, Goater R, Castillo-Ramirez S, Corander J, Colijn C, Chlebowicz MA, Schouls L, Heck M, Pluister G, Ruimy R, Kahlmeter G, Ahman J, Matuschek E, Friedrich AW, Parkhill J, Bentley SD, Spratt BG, Grundmann H, ESCMID Study Group on Molecular Epidemiological Markers, European Staphylococcal Reference Laboratory Working Group. 2016. Whole-genome sequencing for routine pathogen surveillance in public health: a population snapshot of invasive *Staphylococcus aureus* in Europe. *mBio* 7:e00444-16. <https://doi.org/10.1128/mBio.00444-16>.